Completed PHASE1/PHASE2 INTERVENTIONAL 5-arm NCT00895596

Safety and Efficacy Study of LB80380 in the Patients With Lamivudine-Refractory Chronic Hepatitis B

A PhaseII, Open-Label, Multinational, Multi-Centre, Sequential Group, Dose-Escalation Study to Assess the Safety and Antiviral Activity of LB80380 for 12 Weeks in Patients With Lamivudine-Refractory Chronic Hepatitis B

Sponsor: LG Life Sciences

Conditions Chronic Hepatitis B

Interventions LB80380

Updated 6 times since 2017 Last updated: May 7, 2009 Started: Mar 31, 2004 Primary completion: Aug 31, 2006 Completion: Dec 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Chronic Hepatitis B and is currently completed. LG Life Sciences leads this study, which shows 6 recorded versions since 2004 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Feb 2017 — Jan 2021 [monthly]

Completed PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Mar 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

LG Life Sciences

Data source: LG Life Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hong Kong, China
• Seoul, South Korea